In addition, ATO combined with TKI showed synergistic anti‐leukaemia effect on chronic myelogenous leukaemia (CML), which is also caused by BCR‐ABL1 8, 9. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.